Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Solid Tumor Therapeutics Market by Type (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy), By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Solid Tumor Therapeutics Market by Type (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy), By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 137167 3300 Medical Devices & Consumables 377 236 Pages 4.7 (32)
                                          

The global solid tumor therapeutics market is expected to grow at a CAGR of 5.5% from 2021 to 2030. The growth of the market is attributed to the increasing incidence of cancer, rising awareness about cancer and its treatment, and technological advancements in the field of oncology. Chemotherapy drugs are used for treating various types of cancers such as breast cancer, lung cancer, colorectal cancer, prostate cancer and cervical cancer. Chemotherapy drugs are administered intravenously or orally depending on the type and severity of the disease. Hormone therapy drugs are used for treating breast cancers that have estrogen receptors or progesterone receptors. Immunotherapy drugs are used for treating various types of cancers such as lung cancers that have EGFR mutations or HER2-positive breast cancers. Targeted therapy drugs are used for treating various types of cancers such as colorectal carcinoma with KRAS mutation or pancreatic adenocarcinoma with KIT mutation. -The global cancer drug market is expected to grow at a CAGR of 8.2% from 2016 to 2020, reaching $150 billion by 2020. -Cancer drugs are the fastest growing segment in the pharmaceutical industry and are forecasted to reach $150 billion by 2020. -Cancer drugs are the fastest growing segment in the pharmaceutical industry and are forecasted to reach $150 billion by 2020. -Innovative new treatments for cancer have been developed that can be used as an alternative or in conjunction with chemotherapy, radiation therapy, surgery or other treatments such as immunotherapy and targeted therapies which have shown promising results for patients with advanced cancers who have not responded well enough to other treatments.

Industry Growth Insights published a new data on “Solid Tumor Therapeutics Market”. The research report is titled “Solid Tumor Therapeutics Market research by Types (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy), By Applications (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others), By Players/Companies Hoffmann-La Roche, Johnson & Johnson, Novartis, AstraZeneca, Biogen Idec, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Kyowa Hakko Kirin, Abbott Laboratories, Baxter International”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Solid Tumor Therapeutics Market Research Report

By Type

Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy

By Application

Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others

By Companies

Hoffmann-La Roche, Johnson & Johnson, Novartis, AstraZeneca, Biogen Idec, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Kyowa Hakko Kirin, Abbott Laboratories, Baxter International

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

236

Number of Tables & Figures

166

Customization Available

Yes, the report can be customized as per your need.


Global Solid Tumor Therapeutics Industry Outlook


Global Solid Tumor Therapeutics Market Report Segments:

The global Solid Tumor Therapeutics market is segmented on the basis of:

Types

Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Hoffmann-La Roche
  2. Johnson & Johnson
  3. Novartis
  4. AstraZeneca
  5. Biogen Idec
  6. Boehringer Ingelheim
  7. GlaxoSmithKline
  8. Eli Lilly
  9. Kyowa Hakko Kirin
  10. Abbott Laboratories
  11. Baxter International

Global Solid Tumor Therapeutics Market Overview


Highlights of The Solid Tumor Therapeutics Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Chemotherapy
    2. Hormone Therapy
    3. Immunotherapy
    4. Targeted Therapy
  1. By Application:

    1. Breast Cancer
    2. Lung Cancer
    3. Colorectal Cancer
    4. Prostate Cancer
    5. Cervical Cancer
    6. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Solid Tumor Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Solid Tumor Therapeutics Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Solid tumor therapies are treatments that aim to kill cancer cells by attacking their solid form. This contrasts with traditional chemotherapy, which attacks the cancerous cells in liquid form.

Some of the key players operating in the solid tumor therapeutics market are Hoffmann-La Roche, Johnson & Johnson, Novartis, AstraZeneca, Biogen Idec, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Kyowa Hakko Kirin, Abbott Laboratories, Baxter International.

The solid tumor therapeutics market is expected to grow at a compound annual growth rate of 5.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Solid Tumor Therapeutics Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Solid Tumor Therapeutics Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Solid Tumor Therapeutics Market - Supply Chain
   4.5. Global Solid Tumor Therapeutics Market Forecast
      4.5.1. Solid Tumor Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Solid Tumor Therapeutics Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Solid Tumor Therapeutics Market Absolute $ Opportunity

5. Global Solid Tumor Therapeutics Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Solid Tumor Therapeutics Market Size and Volume Forecast by Type
      5.3.1. Chemotherapy
      5.3.2. Hormone Therapy
      5.3.3. Immunotherapy
      5.3.4. Targeted Therapy
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Solid Tumor Therapeutics Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Solid Tumor Therapeutics Market Size and Volume Forecast by Application
      6.3.1. Breast Cancer
      6.3.2. Lung Cancer
      6.3.3. Colorectal Cancer
      6.3.4. Prostate Cancer
      6.3.5. Cervical Cancer
      6.3.6. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Solid Tumor Therapeutics Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Solid Tumor Therapeutics Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Solid Tumor Therapeutics Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Solid Tumor Therapeutics Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Solid Tumor Therapeutics Demand Share Forecast, 2019-2029

9. North America Solid Tumor Therapeutics Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Solid Tumor Therapeutics Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Solid Tumor Therapeutics Market Size and Volume Forecast by Application
      9.4.1. Breast Cancer
      9.4.2. Lung Cancer
      9.4.3. Colorectal Cancer
      9.4.4. Prostate Cancer
      9.4.5. Cervical Cancer
      9.4.6. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Solid Tumor Therapeutics Market Size and Volume Forecast by Type
      9.7.1. Chemotherapy
      9.7.2. Hormone Therapy
      9.7.3. Immunotherapy
      9.7.4. Targeted Therapy
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Solid Tumor Therapeutics Demand Share Forecast, 2019-2029

10. Latin America Solid Tumor Therapeutics Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Solid Tumor Therapeutics Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Solid Tumor Therapeutics Market Size and Volume Forecast by Application
      10.4.1. Breast Cancer
      10.4.2. Lung Cancer
      10.4.3. Colorectal Cancer
      10.4.4. Prostate Cancer
      10.4.5. Cervical Cancer
      10.4.6. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Solid Tumor Therapeutics Market Size and Volume Forecast by Type
      10.7.1. Chemotherapy
      10.7.2. Hormone Therapy
      10.7.3. Immunotherapy
      10.7.4. Targeted Therapy
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Solid Tumor Therapeutics Demand Share Forecast, 2019-2029

11. Europe Solid Tumor Therapeutics Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Solid Tumor Therapeutics Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Solid Tumor Therapeutics Market Size and Volume Forecast by Application
      11.4.1. Breast Cancer
      11.4.2. Lung Cancer
      11.4.3. Colorectal Cancer
      11.4.4. Prostate Cancer
      11.4.5. Cervical Cancer
      11.4.6. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Solid Tumor Therapeutics Market Size and Volume Forecast by Type
      11.7.1. Chemotherapy
      11.7.2. Hormone Therapy
      11.7.3. Immunotherapy
      11.7.4. Targeted Therapy
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Solid Tumor Therapeutics Demand Share, 2019-2029

12. Asia Pacific Solid Tumor Therapeutics Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Solid Tumor Therapeutics Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Solid Tumor Therapeutics Market Size and Volume Forecast by Application
      12.4.1. Breast Cancer
      12.4.2. Lung Cancer
      12.4.3. Colorectal Cancer
      12.4.4. Prostate Cancer
      12.4.5. Cervical Cancer
      12.4.6. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Solid Tumor Therapeutics Market Size and Volume Forecast by Type
      12.7.1. Chemotherapy
      12.7.2. Hormone Therapy
      12.7.3. Immunotherapy
      12.7.4. Targeted Therapy
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Solid Tumor Therapeutics Demand Share, 2019-2029

13. Middle East & Africa Solid Tumor Therapeutics Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Solid Tumor Therapeutics Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Solid Tumor Therapeutics Market Size and Volume Forecast by Application
      13.4.1. Breast Cancer
      13.4.2. Lung Cancer
      13.4.3. Colorectal Cancer
      13.4.4. Prostate Cancer
      13.4.5. Cervical Cancer
      13.4.6. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Solid Tumor Therapeutics Market Size and Volume Forecast by Type
      13.7.1. Chemotherapy
      13.7.2. Hormone Therapy
      13.7.3. Immunotherapy
      13.7.4. Targeted Therapy
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Solid Tumor Therapeutics Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Solid Tumor Therapeutics Market: Market Share Analysis
   14.2. Solid Tumor Therapeutics Distributors and Customers
   14.3. Solid Tumor Therapeutics Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Hoffmann-La Roche
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Johnson & Johnson
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Novartis
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. AstraZeneca
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Biogen Idec
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Boehringer Ingelheim
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. GlaxoSmithKline
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Eli Lilly
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Kyowa Hakko Kirin
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Abbott Laboratories
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Baxter International
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us